Genovis Bio Announces Completion of RMB 100 Million Series C+ Financing to Accelerate Global CDMO Capabilities

Zhenge Biotechnology adheres toInternationalization, ScalabilityDevelopment Direction: To better meet the ever-increasing production capacity demands of domestic and international customers, an investment of over RMB 1.3 billion has been made to establish ultra-large-scale commercial manufacturing capabilities, constructing a facility covering an area of 66,000 square meters in the Lanwan Life Science Industrial Park within the Shanghai Lingang New Area.GMP Commercial Production FacilityandR&D Center. Phase I of the commercial production base is about to be completed and put into operation, includingThree 2,000 L single-use bioreactor production lines and three 5,000 L stainless steel bioreactor production lines. At that time, Shanghai Zhenge Biotechnology Co., Ltd. will become the first CDMO enterprise in China to simultaneously possess multiple production lines for both single-use bioreactors and large-scale stainless steel bioreactors.

Shanghai Zhenge Biotechnology Co., Ltd. upholds the corporate values of “Investigating Things to Bear Responsibility, Striving for Perfection,” remains committed to pursuing excellence in process quality, and has established advanced process technologies, a robust organizational structure, and a high-caliber talent pool, thereby providing the industry withHigh-Quality, High-Efficiency, and Cost-Effective One-Stop CDMO Technical Services, and gradually emerging as a prominent player in the industry.

Mr. Li Ke, General Manager of Sinopharm ZhongjinIt was stated that Sinopharm Zhongjin focuses on the healthcare sector and has actively invested in recent years in innovative service enterprises capable of effectively addressing pain points in pharmaceutical R&D. Due to their high target specificity, superior efficacy, and favorable compliance profile, biologics have become mainstream in the European and American pharmaceutical markets. Shanghai Zhenge Biotechnology Co., Ltd. is a leading enterprise in the CDMO field for biological macromolecules, boasting industry-leading process development capabilities, a strong reputation, and numerous successful project case studies. The company has experienced rapid growth in recent years and has established a commercial-scale biologics production base in Shanghai. It is well-positioned to leverage Shanghai’s talent pool and strategic location advantages in the biopharmaceutical sector to serve pharmaceutical companies both domestically and internationally.

Mr. Gu Jiefeng, Deputy General Manager of Zhangkeherun FundIt was stated that Shanghai Zhenge Biotechnology Co., Ltd. is a leading CDMO company in China’s biopharmaceutical industry. Through years of dedication, the team has established a solid competitive moat in core areas such as early-stage cell line development, media development, upstream and downstream process development, and characterization. The company is now capable of providing more clients with services spanning from IND-enabling studies to commercial-scale manufacturing. We believe that an increasing number of outstanding biopharmaceutical companies will choose Zhenge as their key partner. Zhangjiang Group has long been deeply rooted in Zhangjiang, cultivating its ecosystem and establishing the area as a premier hub for drug R&D in China. As the group’s biomedical investment platform, Shanghai Zhangkeherun Venture Capital Co., Ltd. (Herun Fund) will leverage Zhangjiang’s industrial ecosystem and park resources to support the robust growth of more excellent biomedical enterprises.

LinMs. Qu Xia, General Manager of Ganglanwan CapitalIt was stated that the development of biomacromolecule drugs in China is currently undergoing rapid growth. Shanghai Zhenge Biotechnology Co., Ltd. has gained recognition from numerous biopharmaceutical enterprise clients thanks to its industry-leading technical capabilities. Zhenge Biotechnology has established its presence in Life Blue Bay within the Lingang New Area, constructing a large-scale GMP commercial production base for biologics and an ADC production base. It provides one-stop CDMO services, ranging from R&D to manufacturing, for biopharmaceutical companies across China and around the world. Lingang Blue Bay Capital focuses on niche sectors including biotechnology and pharmaceuticals, medical devices, healthcare services, and AI in biomedicine, and will provide comprehensive support and services to further assist Zhenge Biotechnology.

Ying Taotao, Deputy General Manager of the Biomedical Investment Department at Pudong Sci-Tech Innovationstated that the large-molecule CDMO sector is a field brimming with potential and poised for robust growth. Shanghai Zhenge Biotechnology Co., Ltd. boasts a team with global vision and world-class R&D capabilities, maintaining industry-leading technologies across multiple stages of large-molecule CDMO services. The company helps clients optimize processes, enhance quality, and achieve industry-leading expression levels, thereby truly enabling Chinese pharmaceutical companies to realize their “In China for Global” strategy.

Shanghai Zhenge Biotechnology Co., Ltd. (hereinafter referred to as “Zhenge Biotech”), established in 2017, is a national high-tech enterprise registered in the Lingang New Area of the China (Shanghai) Pilot Free Trade Zone. Zhenge Biotech’s core business focuses on CDMO services for macromolecular biopharmaceuticals and the development and production of mammalian cell culture media. Its service portfolio includes: druggability assessment of macromolecular drugs, turnkey CMC clinical filing support for macromolecular drugs, cell line development, process development and optimization, pilot-scale production, clinical sample manufacturing and commercial CMO services, process characterization and validation studies, analytical testing services, as well as formulation development and commercial production of cell culture media. By providing integrated CDMO services spanning from preclinical research to commercial production, along with domestically produced customized cell culture media products, Zhenge Biotech aims to facilitate and accelerate the R&D and industrialization of macromolecular biopharmaceuticals for pharmaceutical companies both in China and abroad.

Sinopharm CICC was established as a joint venture by Sinopharm Group Co., Ltd., a leading enterprise in China’s medical industry distribution, and CICC Capital, the private equity fund platform under China International Capital Corporation (CICC). Aligned with Sinopharm’s strategic objectives, Sinopharm CICC leverages Sinopharm’s extensive resources in the medical industry and combines them with CICC’s strong capital advantages. By utilizing its team’s professional expertise in investment and capital integration, the company invests in high-quality enterprises in fields such as innovative medical devices, innovative drug research and development, innovative medical services, and pharmaceutical digitalization.

Managed by Zhangjiang Sci-Tech Investment, a wholly-owned subsidiary of Zhangjiang Group, and anchored by the Pudong Science and Technology Innovation Fund of Funds, the Zhangke Herun Fund focuses on innovative drugs, medical devices, healthcare services, and related sectors. As Zhangjiang Group’s biomedical investment platform, the fund leverages Zhangjiang’s industrial ecosystem and park resources to support the growth of high-quality, high-potential enterprises in the life and health industries.

Lingang Lanwan Capital is an industrial investment platform under the Lingang Group, dedicated to the healthcare sector. Based in the Life Bay special industrial park within the Lingang New Area, the platform extends its reach across China and globally. It is committed to optimizing the healthcare ecosystem, integrating superior resources, and empowering high-quality enterprises to achieve sustainable growth. Its mission is to help establish a pioneering zone for precision medicine with global influence and to build a world-class hub for industrial development.

SPINNOTEC is a state-owned venture capital group established by the People’s Government of Pudong New Area to advance the construction of a globally influential science and technology innovation center and promote the development of high-tech industries. Specializing in venture investment, sci-tech financial services, and overseas resource integration, it is one of China’s oldest and most capable state-owned venture capital firms. Haiwang Capital, founded in 2020, serves as the fund operation management platform for SPINNOTEC and is a key vehicle for the group’s market-oriented mechanism innovation. With an excellent investment team, Haiwang Capital has initiated and manages multiple funds, with assets under management exceeding RMB 15 billion.